Related Experiment Video

Updated: Jul 15, 2026

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

CD40 and its ligand in atherosclerosis

Esther Lutgens1, Dirk Lievens, Linda Beckers

  • 1Department of Pathology, University of Maastricht, Cardiovascular Research Institute Maastricht, 6229 HX Maastricht, The Netherlands. e.lutgens@path.unimaas.nl

Trends in Cardiovascular Medicine
|May 8, 2007
PubMed

Insights

Inhibiting CD40-CD40 ligand (CD40L) interactions stabilizes atherosclerotic plaques by increasing collagen and reducing immune cells. Targeting this pathway offers a promising therapeutic strategy for cardiovascular disease with potentially fewer side effects.

Area of Science:

  • Cardiovascular Research
  • Immunology
  • Atherosclerosis Pathogenesis

Background:

  • CD40-CD40 ligand (CD40L) interactions are critical in atherosclerosis development and progression.
  • Complete CD40L pathway inhibition previously demonstrated reduced atherosclerosis and promoted plaque stability.

Purpose of the Study:

  • To explore therapeutic strategies targeting the CD40-CD40L system for atherosclerosis.
  • To investigate methods for inducing plaque stabilization with minimized systemic immune compromise.

Main Methods:

  • Review of studies investigating CD40-CD40L pathway inhibition in atherosclerosis models.
  • Analysis of plaque composition changes (collagen, smooth muscle cells, macrophages, T lymphocytes) following CD40L inhibition.
  • Conceptualization of targeted inhibition strategies for the CD40-CD40L system.

Main Results:

  • Complete CD40L inhibition leads to stable plaques with increased collagen and vascular smooth muscle cells.
  • Stable plaques exhibit reduced macrophage and T lymphocyte infiltration.
  • Long-term systemic CD40L inhibition may compromise immune function.

Conclusions:

  • CD40-CD40 ligand (CD40L) pathway inhibition is a validated therapeutic target for atherosclerosis.
  • Targeting downstream modulators or employing local, cell-specific inhibition may mitigate systemic side effects.
  • Plaque stabilization via targeted CD40-CD40L modulation holds potential for reducing cardiovascular disease morbidity and mortality.

More Related Videos

Quantification of Atherosclerosis in Mice06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

Related Concept Videos

Inflammation01:38

Inflammation

Overview
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...